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ABSTRACT
Objectives: We set out to determine the reasons for serum vedolizumab (VDZ) trough concentration
(TC) measurements in inflammatory bowel disease (IBD) patients and to evaluate treatment modifica-
tions after therapeutic drug measurement (TDM). We also evaluated the effect of increased dosing on
patients’ response to VDZ therapy.
Methods: We performed a retrospective cohort study of IBD patients who received VDZ therapy at
Helsinki University Hospital and whose VDZ levels were measured between June 2014 and
December 2018.
Results: Altogether, 90 patients (32 Crohn’s disease and 58 ulcerative colitis) and 141 VDZ TC meas-
urements were included. 24.1% of measurements took place during induction and 75.9% during the
maintenance phase. During induction, 64.7% reached the target TC >20mg/ml. During maintenance
therapy, 82.2% of VDZ TCs were within or exceeded the suggested target range of 5–15mg/ml.
Reasons for TDM were: secondary nonresponse (44.0%), assessment of adequate VDZ TC (25.5%), pri-
mary nonresponse (12.8%), adverse events (6.4%), and other (11.3%). No treatment changes occurred
after 60.3% of VDZ measurements. Increased dose frequency was used after 25.5% of VDZ measure-
ments and 33.3% of these patients experienced improvement. Altogether, 31 (34.4%) patients discon-
tinued the therapy due to inadequate treatment response. No anti-vedolizumab antibodies
were detected.
Conclusions: During the maintenance of VDZ therapy, the majority of VDZ TCs were within the sug-
gested range. Measurement of VDZ TC did not lead to any treatment changes in two-thirds of
patients. Dose optimization occurred in a quarter of patients and a third of them benefited from it.
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Inflammatory bowel diseases (IBDs) are chronic relapsing and
remitting diseases that impact negatively on patient quality
of life and cause a large financial burden to society. Medical
therapies target restoration of the patient’s quality of life
and prevention of IBD-associated cancer by decreasing
mucosal inflammation [1].
Vedolizumab (VDZ) is a humanized monoclonal antibody
targeting a4b7 integrin and subsequently modulates lympho-
cyte trafficking, resulting in an intestine-specific anti-inflam-
matory effect. The terminal elimination half-life of VDZ has
been estimated to be 25.5 d, and elimination is primarily lin-
ear at therapeutic concentrations [2]. VDZ seems to have a
favourable safety profile [3]. GEMINI 1 and 2 studies proved
VDZ to be effective for induction and maintenance therapy
in moderate to severe Crohn’s disease (CD) and ulcerative
colitis (UC) [4,5], and real-life cohorts have confirmed the
results [6]. On the other hand, loss of response may occur in
VDZ-treated IBD patients. In these situations, drug effects
may be regained with dose intensification [7].
Therapeutic drug monitoring (TDM) is an important tool
in the personalization of care and in optimizing the treat-
ment of patients with inadequate response or a loss of
response. Titration of VDZ to target trough concentration
(TC) is associated with improved clinical outcomes [8,9].
Some clinical factors are found to affect drug concentrations
[10,11]. Anti-TNF-naivety seems to be a positive predictor of
response and mucosal healing [12]. The formation of anti-
drug antibodies (ADA) result in lower serum drug concentra-
tions and decreased drug effectiveness but immunogenicity
is not as significant a problem in VDZ therapy as it is with
anti-TNF therapy. Currently, TDM is an important part of the
routine treatment of IBD patients on anti-TNF therapy since
it has been shown to improve response and remission
rates [13,14].
Some current guidelines suggest proactive TDM after anti-
TNF induction in order to ensure adequate TCs and to avoid
CONTACT Sara Kolehmainen sara.kolehmainen@helsinki.fi Faculty of Medicine, University of Helsinki, Helsinki, Finland.
 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
2021, VOL. 56, NO. 8, 906–913
https://doi.org/10.1080/00365521.2021.1938206
immunization [15,16]. However, due to a lack of existing
data, proactive TDM is not suggested during VDZ therapy.
Only one guideline suggests reactive TDM at the end of VDZ
induction in non-responders and patients with a confirmed
secondary loss-of response [16]. Thus, the role of reactive
TDM during VDZ therapy requires further investigation. The
primary aim of the present study was to determine the rea-
sons for serum VDZ TC measurements and to evaluate treat-
ment modifications after TDM. The secondary aim was to
investigate the effect of increased dosing on patients’
response to VDZ therapy.
Patients and methods
This was a retrospective, non-interventional chart-review
study designed to assess the reasons for VDZ concentration
measurements and the association of VDZ TCs with patient’s
response to VDZ therapy in IBD. All adult IBD patients, who
received VDZ therapy in clinical practice at Helsinki
University Hospital, and whose VDZ concentrations were
measured at least once between 1 June 2014 and 31
December 2018, were included in this study. IBD patients
with available VDZ TCs were identified from the United
Medix Laboratories research register. Data were collected
retrospectively from the electronic health records in a pre-
established anonymous standardized case report form (CRF).
Laboratory measurements and information on concomitant
medications were collected from the hospital IBD registry.
Outcome variables were collected at baseline, induction
phase (defined as 14 weeks of therapy), at month 12, and
the treatment discontinuation or at the end of the follow-up
period, whichever occurred first. In addition, outcome varia-
bles were collected at the time of each VDZ TC measurement
and within 3 months after VDZ treatment modification dur-
ing the maintenance phase.
Definitions of disease activity and treatment response
Clinical disease severity for UC was evaluated using the par-
tial Mayo score (PMS). Baseline PMS 7–9 was considered
severe, 5–6 moderate and 2–4 mild clinical activity, and 0–1
clinical remission. Clinical treatment response was defined as
PMS reduction 3 and a decrease of at least 30% from the
baseline score, and PMS 2 (with no individual subscore >1)
as clinical remission. PMS reduction 2 was considered as no
clinical response [17,18]. In case of inadequate data, clinical
activity was assessed with the physician’s global assessment
(PGA): remission, mild, moderate, or severe disease activity
[19]. Clinical activity for CD was classified dichotomously as
an active or inactive disease based on PGA. The primary
response, nonresponse, and secondary loss of response were
based on the clinician’s evaluation.
The following laboratory parameters were recorded:
haemoglobin, leucocytes, thrombocytes, albumin, C-reactive
protein (CRP), and faecal calprotectin (F-calprotectin). F-cal-
protectin <100 mg/g was considered normal. Laboratory tests
had been carried out as part of the routine clinical practice.
VDZ infusions, VDZ TCs and anti-VDZ antibody
measurements
Dates of VDZ infusions and measurement of VDZ concentra-
tion and anti-vedolizumab antibody (AVA) levels were col-
lected, and infusion schedule during induction and
maintenance therapy was determined based on these data.
Reasons for measurement of VDZ concentrations and AVAs
were recorded and classified as primary nonresponse, sec-
ondary nonresponse (including loss of response and inad-
equate total response), assessment of adequate VDZ
concentrations during induction/maintenance therapy,
adverse effects, or other reason (e.g., physician’s interest to
receive the clinical experience of use of VDZ TDM).
Treatment changes following VDZ measurements were
recorded. Possible treatment changes were increased or
decreased dose frequency, treatment discontinuation, switch
to another biological, or other change. Other treatment
changes included surgical treatment and the addition of
another biological to the patient’s therapy. Effects of treat-
ment changes were classified as no observed change, moder-
ate improvement (noticeable decrease in clinical activity),
and significant improvement (meaning clinical remission).
VDZ concentrations were analysed with an enzyme-
immunological assay and serum AVAs with a radioimmuno-
assay (Sanquin, Amsterdam, the Netherlands). VDZ TC target
was defined as >20mg/ml during induction therapy [20] and
5–15 mg/ml during maintenance therapy according to the
laboratory reference.
Statistical analysis
Baseline demographic and treatment data were analysed
using descriptive statistics and are reported as mean and
standard deviation (SD). The comparison between groups
was analysed using generalized linear models and point esti-
mates and 95% confidence intervals are presented. Changes
from baseline to follow-up (i.e., laboratory outcomes and effi-
cacy variables) were analysed using a paired sample t-test.
Additionally, the differences between variables at baseline
and follow-up were analysed using the Fisher Exact Test,
Wilcoxon signed-rank test, the Mann–Whitney U-test, and the
Marginal Homogeneity test. A receiver operating characteris-
tic (ROC) analysis was performed for VDZ concentrations to
trace the threshold associated with response to induction
therapy. These statistical analyses were conducted using R
(version 3.4.0 or higher, http://www.r-project.org), Stata (ver-
sion 13.0 or higher, StataCorp. 2013. Stata Statistical
Software: Release 13. College Station, TX: StataCorp LP), and
IBM SPSS Statistics (Version 25.0 or higher). All p-values were
two-tailed and p< .05 was considered statistically significant.
Ethical consideration
No ethics approval or informed consent from the cohort was
required by Finnish legislation, as the persons were not
contacted, the study did not affect the treatment of
the patients, and only pseudonymized data were used.
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Research permission for data collection was applied from the
study centre (HUS research permission number HUS/333/2019).
Results
Baseline characteristics
Altogether 90 patients (32 CD and 58 UC) were included. The
baseline characteristics, disease activity, and treatment his-
tory of the patients are shown in Tables 1 and 2. The major-
ity of patients, 71.9% of CD and 89.7% of UC patients, were
previously treated with at least one other biological drug.
Approximately, a third of the CD patients (28.1%) were
treated with corticosteroids, 3.1% with 5-ASA or sulfasalazine,
and 12.5% with immunosuppressants as a concomitant ther-
apy at the baseline. The corresponding figures for the UC
patients were 32.8%, 34.5%, and 46.6%. The median number
of VDZ infusions per patient during follow-up was 12 (min-
imum 2, maximum 31 infusions). Altogether, 13 (14.4%, 6 CD
and 7 UC) patients received an additional VDZ infusion on
week 10. The median length of VDZ therapy was 17.0
months (min <1 month, max 52 months). No significant dif-
ference in the length of VDZ therapy between CD and UC
patients was detected (p> .05).
VDZ concentration measurements
Altogether, 141 VDZ TCs were measured during the study
period: 34 (24.1%; CD n¼ 10, UC n¼ 24) of these measure-
ments occurred during the induction phase and 107 (75.9%;
CD n¼ 44, UC n¼ 63) during the maintenance phase. An
analysis of VDZ TC, 56 (62.2%) patients were measured once,
24 (26.7%) patients twice, 6 (6.7%) patients three times, and
4 (4.4%) patients four or more times. Altogether, 24 AVA
measurements were performed during the induction or
maintenance phase but no AVAs were detected.
The effect of patient characteristics on VDZ
concentration
Age, gender, and disease duration had no statistically signifi-
cant correlation with VDZ TCs during the induction or main-
tenance phase (p> .05 for age, gender, and diagnosis).
During the induction phase, VDZ TC was observed to be sig-
nificantly lower in patients with body mass index (BMI) 25
(p¼ .004) or BMI >30 (p¼ .031) compared with patients with
normal BMI. During the maintenance phase, no significant
difference in VDZ TC was observed with BMI 25 or 30
compared with patients with normal BMI.
VDZ concentration during the induction phase
During the induction phase, the mean VDZ TC was 25.1 mg/
ml (SD 11.5) and ranged between 1.7 mg/ml and 49 mg/ml. Of
34 VDZ TC measurements performed during the induction,
21 (61.8%) were made before week 8, 5 (14.7%) between 8
and 12 weeks, and 8 (23.5%) between 12 and 14 weeks after
initiation of VDZ therapy. Of these, 22 (64.7%) VDZ TCs
reached the defined target level >20 mg/ml and 12 (35.3%)
remained below the target (Figure 1). A ROC curve analysis
identified a statistically significant VDZ concentration thresh-
old of 19 mg/ml associated with response to induction
(Figure 2). We also assessed whether differences in VDZ con-
centrations during the induction phase impacted either the
clinical activity (PMS/PGA in UC, inactive/active disease in
CD) or biomarker-based disease activity (F-calprotectin or
CRP) but no relationship between the two was observed.
Considering all measurements during induction, 11 measure-
ments that resulted from primary nonresponse had a mean
concentration of 17.1 mg/ml, and the other 21 measurements
had a mean concentration of 28.5mg/ml (p¼ .004).
VDZ concentration during the maintenance therapy
The mean duration between the first VDZ infusion and VDZ
TC measurement was 14.2 months (min 3.2, max 49.8
months). Of the 107 VDZ TCs measured during the mainten-
ance phase, 38 (35.5%) reached the defined target level of
5–15 mg/ml and 50 (46.7%) exceed it (Figure 3). Therefore, 19
(17.8%) measurements remained below the target level of
5–15 mg/ml. Mean VDZ TC was 16.9mg/ml (SD 11.4) and
ranged between 0.2mg/ml and 60.0 mg/ml. Measurements
because of non-responsiveness had a mean concentration of
17.3 mg/ml and other measurements a mean concentration of
16.3 mg/ml (p> .05).
Reasons for VDZ concentration measurement
VDZ concentrations were measured based on the physician’s
clinical consideration. The reasons for the measurements are
presented in Table 3. Of all measurements, 18 (12.8%) were
performed due to primary nonresponse. Secondary nonres-
ponse, including secondary loss of response and inadequate
total response, was the most common indication for VDZ
measurement (44.0%). A quarter (25.5%) of VDZ TC measure-
ments were performed to confirm adequate VDZ levels. A
minority (6.4%) of all VDZ measurements were performed
because of adverse events. The rest of the measurements
(11.3%) were performed due to other or unknown indica-
tions, mainly because of the physician’s interest.
Treatment changes after VDZ measurement
Any changes in therapy were recorded; after 60.3% of meas-
ured VDZ concentrations no treatment changes were per-
formed (Table 4). Optimization of the VDZ therapy by
increasing dose frequency occurred after 25.5% of the meas-
urements, whereas a decrease in dose frequency was made
in two cases (1.4%). The shortest observed dosing interval
was 2.4 weeks. Switch to another biological or discontinu-
ation of VDZ therapy resulted after 9.2% of VDZ measure-
ments. Other treatment changes (colectomy, combination
VDZ with golimumab therapy) were made after 4 (2.8%)
measurements.
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Table 1. Patient characteristics and disease phenotype at baseline.
Crohn’s disease (n¼ 32) Ulcerative colitis (n¼ 58)
n Mean (SD) n Mean (SD)
Age (years) 32 46.6 (18.6) 58 43.2 (16.6)
Disease duration (years) 32 15.9 (10.7) 58 10.0 (8.5)
BMI 31 26.4 (5.63) 56 26.2 (5.27)
Gender n % n %
Female 17 53.1 19 32.8
Male 15 46.9 39 67.2
Smoking n % n %
No 22 68.8 47 81.0
Yes 4 12.5 2 3.4
Unknown 6 18.8 9 15.5
Montreal classification n % n %
A1 7 21.9 – –
A2 19 59.4 – –
A3 6 18.8 – –
L1 6 18.8 – –
L2 4 12.5 – –
L3 21 65.6 – –
L4 8 25.0 – –
B1 9 28.1 – –
B2 13 40.6 – –
B3 10 31.2 – –
Perianal disease 8 25.0 – –
E1 – – 1 1.7
E2 – – 18 31.0
E3 – – 39 67.2
Extraintestinal manifestations n % n %
Any 8 25.0 8 13.8
Arthritis 2 6.2 3 5.2
Pyoderma gangrenosum, erythema nodosum 5 15.6 3 5.2
Primary sclerosing cholangitis 1 3.1 2 3.4
Abbreviation: BMI: body mass index.
Table 2. Disease activity and treatment history at baseline.
Crohn’s disease (n¼ 32) Ulcerative colitis (n¼ 58)
Clinical activity n % n %
UC: PMS (n¼ 34) / PGA (n¼ 24)
Remission – – 8 13.8
Mild – – 23 39.7
Moderate – – 25 43.1
Severe – – 2 3.4
CD: PGA
Active 21 65.6 – –
Inactive 11 34.4 – –
Laboratory parameters n Mean (SD) n Mean (SD)
Haemoglobin, g/l 31 132.4 (17.7) 54 131.4 (17.8)
Leucocytes, E9/l 31 8.3 (2.6) 54 8.5 (3.1)
Platelets, E9/l 31 339.1 (97.7) 54 327.8 (104.2)
CRP, mg/l 22 19.8 (29.7) 24 8.2 (6.5)
Faecal calprotectin, mg/g 26 951.8(1746.6) 49 1442.9(1968.6)
Other medication n % n %
Corticosteroids 9 28.1 19 32.8
5-ASA/sulfasalazine 1 3.1 20 34.5
Immunosuppressants 4 12.5 27 46.6
Other 3 9.4 6 10.3
Previous biological therapies n % n %
0 9 28.1 6 10.3
1 5 15.6 47 81.0
2 13 40.6 5 8.6
3 5 15.6 0 0.0
Adalimumab 20 87.0 4 7.7
Infliximab 20 87.0 48 92.3
Golimumab 2 8.7 5 9.6
Ustekinumab 6 26.1 0 0.0
Previous surgical therapy 18 56.3 0 0.0
Abbreviations: UC: ulcerative colitis; PMS: partial Mayo Score; CD: Crohn’s disease; PGA: Physician’s Global Assessment; 5-ASA:
5-aminosalicylic acid.
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The effects of increased dosing frequency
Mean VDZ TC preceding increased dosing frequency was
10.4mg/ml (SD 8.4). Of patients with increased dose fre-
quency, 15 (41.7%) had no observed change in clinical
response. Moderate improvement was observed in 9 (25.0%)
patients and significant improvement (remission) in 3 (8.3%)
of the patients (Table 5). Twenty-one (58.3%) patients had
VDZ TC measured also after dose intensification with a mean
VDZ TC of 20.6 mg/ml (SD 11.1). VDZ concentration increased
by an average of 11.6mg/ml. After dose intensifications, there
was no significant difference in VDZ TC among patients with
no observed change in treatment response nor in patients
with moderate or significant improvement (p> .05).
Treatment persistence and discontinuation
VDZ treatment was discontinued in 37 (41.1%) patients and
occurred mainly (n¼ 31, 83.8%) due to inadequate response
to therapy (Table 6). No significant difference in VDZ TC
between patients who continued the therapy and the ones
who discontinued was observed (p> .05). Adverse events
(arthralgia, infusion reaction, infection) were the cause of
VDZ discontinuation in 8.1% of patients. Other causes for dis-
continuation were the patient’s will, remission, and recurrent
pyogenic cholangitis. At six months after treatment initiation,
88.0% of UC and 91.0% of CD patients remained on treat-
ment. Increased dose frequency had no effect on treatment
persistence compared to patients with no dose intensifica-
tion (p> .05). Also, no significant differences between CD
and UC on drug persistence were detected (p> .05).
Discussion
TDM has the potential to improve treatment outcomes in
VDZ therapy but thresholds for optimal drug exposure and
the effect of dose optimization are yet to be defined [21]. In
the present study, we set out to investigate the reasons and
benefits of reactive TDM in the optimization of VDZ therapy.
The most usual reason for the measurement of VDZ TC was
an inadequate response to therapy and the majority of
measurements (75.9%) took place in the maintenance phase.
During the maintenance phase, reactive TDM resulted in the
optimization of VDZ dose interval in approximately a quarter
of patients. Improvement in treatment response was
observed in 9.1% of CD and 44.0% of UC patients with
increased dosing frequency. A third of patients discontinued
the therapy due to a lack of adequate response despite the
VDZ TC.
TDM is an important tool in the personalization of care
and in optimizing treatment efficacy in patients with primary
nonresponse or secondary loss of response during the anti-
TNF therapy. By contrast, no robust target induction VDZ
level is available for routine use. The largest VDZ concentra-






















All, n=34 CD, n=10 UC, n=24
Figure 1. Vedolizumab trough concentrations during the induction therapy.
Figure 2. ROC analysis for vedolizumab serum concentration after induction























All, n=107 CD, n=44 UC, n=63
Figure 3. Vedolizumab trough concentrations during the maintenance therapy.
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GEMINI studies. The GEMINI I and II studies have shown that
during induction (week 6) the patients with VDZ concentra-
tions in the highest quartiles achieved clinical response and
remission more often than patients in the lowest quartiles
[4,5]. In an analysis of GEMINI I patients, week 6 VDZ concen-
tration was identified as the earliest time at which the con-
centration (>37.1lg/ml) was associated with clinical
remission after induction or at one year [22]. However,
uncontrolled retrospective and prospective cohort studies
have detected lower VDZ concentration thresholds at week 6
for clinical or endoscopically favourable outcomes [9,10,23].
A recent review suggested a target level of 20lg/ml at week
6 during induction to be associated with improved clinical
outcomes [20].
In our study, only a quarter of all VDZ measurements
were performed during the induction phase, the most com-
mon reason being an inadequate response to therapy. Of
these, 64.7% reached the suggested target level of >20 lg/
ml. In a quarter of patients, almost all being UC patients,
measurement of VDZ concentration resulted in optimization
of dosing. However, no association with clinical or bio-
marker-based outcomes was detected after induction. This
contradicts other recently published cohort studies that have
been suggesting an association between VDZ concentration
and clinical activity scores and biochemical markers [24–25].
Real-world studies have confirmed that VDZ is able to
maintain long-term clinical remission in the treatment of IBD
patients [6]. In a French national multi-centre cohort study
three-year VDZ treatment persistence rates were 26.3% in
patients with CD and 42.9% in patients with UC [26]. A
Higher VDZ level at week 14 may predict higher VDZ treat-
ment persistence over the first year [27]. Increasing dosing
frequency from every 8 to every 4 weeks may benefit some
patients. In the above-mentioned French study just over half
of the VDZ-treated IBD patients experienced infusion sched-
ule intensification [26]. In our selected patient population,
the optimization of VDZ therapy by increasing dose fre-
quency occurred after a quarter of the measurements.
Target maintenance VDZ concentration remains unclear.
Complete saturation of the a4b7 receptors of peripheral
Table 3. Reasons for vedolizumab concentration measurements during the induction and maintenance phases.
Crohn’s disease (n¼ 54) Ulcerative colitis (n¼ 87)
Induction phase (n¼ 34) n % n %
Primary nonresponse 4 40.0 8 33.3
Secondary nonresponse 0 0.0 3 12.5
Assessment of adequate VDZ concentration 3 30.0 12 50.0
Adverse event 2 20.0 1 4.2
Other/unknown 1 10.0 0 0.0
Maintenance phase (n¼ 107)
Primary nonresponse 1 2.3 5 7.9
Secondary nonresponse 25 56.8 34 54.0
Assessment of adequate VDZ concentration 12 27.3 9 14.3
Adverse event 2 4.5 4 6.3
Other/unknown 4 9.1 11 17.5
Abbreviation: VDZ: vedolizumab.
Table 4. Treatment changes after vedolizumab trough concentration measurements.
Crohn’s disease (n¼ 54) Ulcerative colitis (n¼ 87)
Induction phase (n¼ 34) n % n %
No treatment changes 7 70.0 15 62.5
Increase in dose frequency 1 10.0 8 33.3
VDZ switched to another biological 1 10.0 1 4.2
Unknown 1 10.0 0 0.0
Maintenance phase (n¼ 107) n % n %
No treatment changes 26 59.1 37 58.7
Increase in dose frequency 10 22.7 17 27.0
Decrease in dose frequency 2 4.5 0 0.0
Treatment discontinuation, no re-initiation 2 4.5 1 1.6
VDZ switched to another biological 3 6.8 5 7.9
Other 1 2.3 3 4.8
Abbreviaiton: VDZ: vedolizumab.
Table 5. Effect on treatment response in patients with increased dos-
ing frequency.
Crohn’s disease (n¼ 11) Ulcerative colitis (n¼ 25)
n % n %
No observed changes 5 45.5 10 40.0
Significant improvement 0 0.0 3 12.0
Moderate improvement 1 9.1 8 32.0
Unknown 5 45.5 4 16.0
Table 6. Reasons for vedolizumab therapy discontinuation.
Crohn’s disease (n¼ 11) Ulcerative colitis (n¼ 26)
n % n %
Primary nonresponse 3 27.3 2 7.7
Secondary loss of response 0 0.0 5 19.2
Inadequate total response 6 54.5 15 57.7
Adverse effects 2 18.2 1 3.8
Other 0 0.0 3 11.5
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lymphocytes already occurs at a VDZ concentration of 1 mg/
ml, during VDZ maintenance therapy every eight weeks [2].
Despite this receptor saturation, an exposure-response rela-
tionship is detected during VDZ maintenance therapy [4–5].
In a large real-world cohort of 258 IBD patients, higher VDZ
concentrations (11.5mg/ml) during the maintenance phase
were observed to significantly associate with corticosteroid-
free clinical and biochemical remission [28]. However, a
recent review suggested serum VDZ TC level of 5.1–11.0 mg/
ml during the maintenance phase is associated with
improved clinical and endoscopic treatment results [29].
During the maintenance phase, the target VDZ concentration
in our study was 5–15 lg/ml as suggested by the laboratory.
Even though a majority of VDZ concentration measurements
were performed because of inadequate response to the ther-
apy, two-thirds of VDZ concentrations were within the sug-
gested target range. Only a fifth of maintenance VDZ
concentrations was below the target level.
Treatment modification after TDM and the effects of these
treatment changes are relevant interests when evaluating
the true beneficial effect of VDZ level measuring. In our
study, the majority of VDZ concentration measurements did
not lead to any treatment changes. It is possible that the
suggested target VDZ maintenance concentration 5–15 lg/ml
guided the clinician to be satisfied with the dosing and not
to try dose intensification. There may be patients in our
study that could have benefited from dose intensification
regardless of VDZ concentration being within the suggested
range. Only a quarter of patients experienced dose optimiza-
tion and a third of them experienced clinical improvement.
In a recent review and meta-analysis, 53.8% of secondary
non-responders restored response after dose intensification
[7]. This is in line with our results as 41.7% of patients with
VDZ treatment intensification experienced no change in
treatment response. The above-mentioned blocking of integ-
rin a4b7 receptors seems to occur regardless of serum VDZ
concentration or response to treatment and has been sus-
pected to contribute to the inefficacy of dose escalation in
VDZ therapy [8,11].
Several factors have been observed to affect the pharma-
cokinetics of VDZ in IBD patients; high BMI and low serum
albumin levels are clinically significant predictors of increased
VDZ clearance [11]. In this study, we detected significantly
higher VDZ concentration in patients with a normal BMI
compared to patients with abnormal BMIs. In contrast to
weight-based dosing with infliximab, vedolizumab has equal
dosing for all patients according to the label [30].
Furthermore, contrary to anti-TNF therapy where immuniza-
tion risk is high and the outcome of therapy is improved in
combination with immunomodulators, immunogenicity with
VDZ therapy is rare as only 3–4% of patients on VDZ therapy
are positive for AVAs [3]. Additionally, the presence of AVAs
does not seem to influence clinical outcomes and is often
transient [8]. Outcomes of vedolizumab monotherapy versus
combination therapy with immunomodulators seem to be
similar [31]. However, a quarter of all patients in our study
were still using combination therapy and, interestingly, the
majority were UC patients. AVAs were not detected in this
patient cohort.
The real-world retrospective study design has well-known
strengths and limitations. By including only patients who
had VDZ concentrations measured, we have selected the
patients with a more unfavourable response to therapy com-
pared with patients in no need of VDZ concentration meas-
urements. Due to the retrospective study design, the
availability of data for collected variables was limited at spe-
cific time points because clinical check-ups and laboratory
tests had been carried out as a part of clinical practice.
Endoscopic data were not available. However, real-world
data from a single referral centre provides valuable evidence
and the cohort is representative of the real-world
patient population.
In conclusion, there is a major need to optimise biological
therapy in order to improve treatment results. Based on the
results in this study, VDZ TDM does not seem to have a
major beneficial impact on treatment outcomes.
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